ACL Digital and PhoenixAI.tech Partner to Take AI-Driven Drone Technology to New Heights

The strategic partnership enhances ACL Digital’s capabilities with PhoenixAI.tech, focusing on AI drone solutions for UAVs, IoT, and edge computing to revolutionize operations significantly Beyond Visual Line of Sight (BVLOS) missions. - March 16, 2024 - ACL Digital

iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

iView Therapeutics Inc., a clinical stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, announces that the U.S. Food and Drug Administration (FDA) cleared iView’s Investigational New Drug (IND) application to for the initiation of a Phase 1/2 clinical... - March 11, 2024 - iView Therapeutics Inc.

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Therapeutics Inc. announces to present the positive topline result in the Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis in the upcoming 2024 ARVO (The Association for Research in Vision and Ophthalmology) national meeting in Seattle, WA. The Presentation... - February 28, 2024 - iView Therapeutics Inc.

GENINVO, a Leading Provider of Life Science Product and Business Solutions Announced the Offering of Its On-Demand Service/Tool: ApoGI™

ApoGI™ is an integrated, one stop automation platform that leverages Artificial Intelligence and Machine Learning algorithms to focus on standards and metadata driven generation of artifacts. The Primary objective of this platform is to help SMEs (Subject matter experts) focus on curating... - February 15, 2024 - GenInvo, Inc.

New Sustainable Lyophilization Technology Uses Supercritical CO2

The Thar group of companies have been using CO2 for extraction, purification, particle design and encapsulation for many years but recent developments point to a need for sustainable methods for drying APIs, intermediates, excipients and biologics at relatively low temperatures. 'Big Pharma' has depended on Thar for SFC tools in drug discovery but lyophilization will likely be used in manufacturing too. - January 28, 2024 - Thar Process, Inc.

Empowering Data Privacy: GENINVO Offers Anonymization as a Service

GENINVO, a leading provider of life science product and business solutions announced the offering of its on-demand service Anonymization as a Service. GENINVO a trailblazer in data privacy solutions, is excited to introduce its ground-breaking offering, Anonymization as a Service. With data... - December 14, 2023 - GenInvo, Inc.

GenInvo Part of PHUSE US Connect & Informa Connect Clinical Data Disclosure, Transparency & Plain Language Summaries Event - 2023

GENINVO was a part of 2 recent global events for the life science industry. The first was "PHUSE US Connect 2023" which was held in Renaissance Orlando at SeaWorld Florida on 5th – 8th March 2023 and the second event, Informa Connect Clinical Data Disclosure, Transparency &... - June 05, 2023 - GenInvo, Inc.

GENINVO Launches Its Latest Offering – Datalution

GenInvo, a leading provider of life science product and business solutions announced the launch of its new, on-demand service: Datalution. GenInvo has recognized various challenges the pharmaceutical industry faces, especially in generating data for clinical trials. The need of clinical data to... - March 11, 2023 - GenInvo, Inc.

GENINVO Service Offering Custom Application Development

GENINVO is a leading provider of high-quality, innovative life science tools. GENINVO understand the business challenges of enterprises big and small. Whether you need short-term, focused design support or turnkey product development, GENINVO has the right tools to meet your needs with the help of... - September 07, 2022 - GenInvo, Inc.

Peptineo, LLC Selected by EPA to Provide EPA Nationwide Coverage for Point of Care (POC) COVID-19 Testing

The Environmental Protection Agency (EPA), Cincinnati Acquisition Division (CAD), has awarded Peptineo LLC, an emerging aerospace, health services, and defense solutions company, a three-year Blanket Purchase Agreement (BPA) to support a comprehensive COVID-19 testing program in support of the... - August 07, 2022 - Peptineo

Global Cancer Technology Successfully Concludes Glioblastoma Pre-Clinical Animal Studies with Impressive Results

Global Cancer Technology Successfully Concludes Glioblastoma Pre-Clinical Animal Studies with Impressive Results

Global Cancer Technology, a San Diego, CA biotechnology company, has successfully completed animal testing with GCT.GLIO.1, a PI3K selective inhibitor that can cross the blood brain barrier and modulate immune cell function. The company will advance the compound to Phase 1 clinical trials as a next step. - July 08, 2022 - Global Cancer Technology

GENINVO Launches Its Latest Offering - Innovation as a Service

GENINVO, a leading provider of life science product and business solutions announced the launch of its new, on-demand service: Innovation as a Service. GENINVO has recognized various challenges the pharmaceutical industry faces, especially in the wake of the pandemic. The need to expedite clinical... - June 12, 2022 - GenInvo, Inc.

Biopharma Industry Standout Robert Proulx Joins Advisory Board of Global Cancer Technology

Biopharma Industry Standout Robert Proulx Joins Advisory Board of Global Cancer Technology

Global Cancer Technology is developing innovative treatments for deadly diseases like cancer, with a current focus on glioblastoma and breast cancer. To date, Mr. Robert Proulx has held numerous Board positions, is a recognized thought leader in biopharma, and currently holds dual roles as the founder and CEO of Imagion Biosystems. - May 21, 2022 - Global Cancer Technology

GENINVO Launches Centre of Excellence for Data Science and Analytics to Help Clients Unlock Insights Using Data Science

GENINVO, a leading provider of life sciences product and business solutions organization, announced the launch of a Centre of Excellence for Data Science and Analytics (DSA CoE). The DSA is a resolute team of experts comprising of life science and technology domains. Data Science and Analytics CoE... - November 18, 2021 - GenInvo, Inc.

Noble Paws CBD Joins Forces with Leading Pet Diabetes Brand

Noble Paws CBD Joins Forces with Leading Pet Diabetes Brand

The pet CBD brand with an ethos, Noble Paws, donates a bottle of their healing CBD to a shelter every time one is purchased. Noble Paws has joined forces with rising star pet diabetes brand, PetTest, to reach as many pets as possible and “hemp” spread the word. - November 04, 2021 - Noble Paws

GENINVO Launches Updated New Website

After months of hard work and dedication, GENINVO is pleased to announce the new and updated website launch. The primary goal of the redesign process was to create a user-focused design, add improved functionality, and provide easy access to information about GENINVO’s products and services. - June 14, 2021 - GenInvo, Inc.

AltuCell Therapeutics Announces Proof-of-Concept in Lead Programs in Type 1 Diabetes in Human Subjects; Phase 1 Pilot in Humans Has IND Approval & Trial to Begin Shortly

AltuCell Therapeutics, Inc., AltuCell announced today the achievement of approval of IND in Italy after pre-clinical proof-of-concept based on data from its two lead programs for type 1 diabetes testing of cadaver stem cell-derived islets in both human and non-human subjects. Their capsules have been implanted in people with diabetes for 5 year, demonstrating long-term safety, with no toxicity or tissue necrosis, and no rejection in any of the patients treated. - January 15, 2021 - AltuCell Therapeutics

A Novel Treatment Modality for COVID-19: Global Cancer Technology is Developing a Nanoparticle Which May Selectively Target, Bind and Inactivate Coronavirus Virions

A Novel Treatment Modality for COVID-19: Global Cancer Technology is Developing a Nanoparticle Which May Selectively Target, Bind and Inactivate Coronavirus Virions

Global Cancer Technology, an emerging biopharmaceutical company, is developing a novel treatment modality to selectively kill the COVID-19 virus. - December 30, 2020 - Global Cancer Technology

3Sixty Pharma Solutions Announces Successful Approval of FDA Investigational New Drug Application

3Sixty Pharma Solutions LLC., www.3sixtypharma.com, has announced the successful submission to FDA, and approval of, an Investigational New Drug (IND) Application on behalf of one of its clinical-stage biotech clients. 3Sixty Pharma Solutions’ 360 Start-Up arm continues to be committed to... - October 15, 2020 - 3Sixty Pharma Solutions

Part B Access for Seniors and Physicians (ASP) Coalition Statement Regarding the Trump Administration’s Recently Announced Executive Order

The Part B Access for Seniors and Physicians (ASP) Coalition released the following statement regarding the Trump Administration’s recently announced Executive Order: “In a letter to lawmakers in 2018, the ASP Coalition warned about the International Pricing Index Model (IPI) and the... - July 24, 2020 - Part B Access for Seniors and Physicians Coalition

GENINVO Celebrates Its Anniversary

A year ago, GENINVO was carved out of a CRO to provide innovative technology solutions and services to the life sciences industry to enable them to deliver drugs faster with higher quality and cost-efficiency. Today GENINVO is partnering with all sizes of Biopharma companies around the world and we... - July 10, 2020 - GenInvo, Inc.

GENINVO CEO Shweta Shukla Announces Upcoming Launch of Shadow(TM) Version2

GENINVO would like to thank its teams for staying on track during these stressful times. While it is easy to lose focus of what is important during this unexpected COVID-19 time, the teams are working from home and have used this as an opportunity to bond with their teammates and collaborate with... - June 18, 2020 - GenInvo, Inc.

Experimentica Ltd. Announces the Successful Acquisition of the Ophthalmic Contract Research Division from Ophthy-DS, Inc.

Experimentica Ltd. Announces the Successful Acquisition of the Ophthalmic Contract Research Division from Ophthy-DS, Inc.

Experimentica Ltd., a leader in preclinical ophthalmic drug discovery services, announces the successful acquisition of the contract research division from Ophthy-DS, Inc., a Michigan-based preclinical contract research organization (CRO) specializing in non-regulated drug discovery services and medical device testing for ophthalmic indications. - May 22, 2020 - Experimentica Ltd

GenInvo Supports Pharma Companies Working to Find a Cure for COVID-19 Virus, as Well as Supporting Their Employees as They Work from Home

GenInvo strives to support the drug development process to find treatments quickly and cost effectively. They are a dedicated part of the solution. Having their employees work from home, not only keeps the employees' and their family's healthy, it also keeps the company on track for developing life-saving solutions and innovative products to the Life Science/Pharma Industry faster. - April 01, 2020 - GenInvo, Inc.

3Sixty Pharma Solutions Partners with Westchester Biotech Project

3Sixty Pharma Solutions Partners with Westchester Biotech Project

Leveraging its “360Start-Up” Powerhouse to Grow a Dynamic Non-Profit for Scientists - January 11, 2020 - 3Sixty Pharma Solutions

GenInvo Launch

GenInvo launches to provide innovative and transformative solutions to the pharma industry to help bring life-changing treatments to patients faster. - December 23, 2019 - GenInvo, Inc.

3Sixty Pharma Solutions Announces Successful Submission of Start-Up Biotech Investigational New Drug Application

3Sixty Pharma Solutions LLC, www.3sixtypharma.com, last week announced the successful submission to FDA of its first Investigational New Drug (IND) Application on behalf of one of its start-up biotech clients. This news comes on the heels of the formal organization in 2018 of 3Sixty Pharma... - December 16, 2019 - 3Sixty Pharma Solutions

RE Pharmacy Opens New Infusion Center in San Diego, CA

As RE Pharmacy progresses forward as a leader in the specialty pharmacy and infusion therapy industry, they have opened a new infusion center located inside the medical building at 7625 Mesa College Drive in San Diego. It shares the second floor with Neurologist Dr. Ian Purcell MD, PhD., boasts... - December 11, 2019 - River's Edge Pharmacy

RE Pharmacy Announces New Infusion Center in Phoenix, AZ

RE Pharmacy Announces New Infusion Center in Phoenix, AZ

RE Pharmacy announces a new infusion center, in partnership with neurologist David Saperstein, MD and the the Center of Complex Neurology in Phoenix, AZ. - October 03, 2019 - River's Edge Pharmacy

New Xcenda White Paper Discusses Why the International Pricing Index Model is Not the Answer to Reforming Medicare Part B

White Paper Highlights Impact of IPI Model on Patients and Health Care Providers - May 09, 2019 - Part B Access for Seniors and Physicians Coalition

RE Pharmacy Announces New Headquarters to Accommodate Rapid Growth

RE Pharmacy Announces New Headquarters to Accommodate Rapid Growth

After years of expansion, RE Pharmacy is pleased to announce the moving of their corporate headquarters. Located in Irvine, California, the two-story headquarters was chosen for its ample space and open floorplans. The layout of the building will allow for added employees and possible pharmacy... - April 19, 2019 - River's Edge Pharmacy

RE Pharmacy Announces New Website Launch

RE Pharmacy Announces New Website Launch

RE Pharmacy, a leader in specialty pharmacy and infusion services, announced today their newly designed corporate website, https://www.repharmacy.com. The overhauled website features streamlined and simplified mobile viewability, improved functionality, and enriched content. The purpose of the new... - April 17, 2019 - River's Edge Pharmacy

Are Antioxidants the Solution to Burning and Itchy Eyes?

A recently published study in The Ocular Surface journal authored by Experimentica Ltd. in collaboration with researchers from Loyola University Chicago and the University of Missouri – Kansas City suggests that a topical antioxidant formulation can improve the pathological signs associated with dry-eye disease. - March 26, 2019 - Experimentica Ltd

Patient & Provider Groups Oppose Legislation to Enable International Reference Pricing for Seniors’ Drugs

Coalition believes proposal by Sen. Sanders, Reps. Khanna and Cummings is likely to restrict access to lifesaving medicines and lead to adverse unintended consequences. - January 11, 2019 - Part B Access for Seniors and Physicians Coalition

339 Groups Urge Congress to Halt International Pricing Index Model

Part B Access for Seniors and Physicians Coalition-organized letter highlights model’s threats to patient choice and American healthcare innovation. - December 18, 2018 - Part B Access for Seniors and Physicians Coalition

New Report: ASP Rates Do Not Encourage Doctors to Prescribe High-Cost Drugs.

Coalition stresses findings of new report as policymakers consider potentially harmful changes to the Medicare Part B program - December 18, 2018 - Part B Access for Seniors and Physicians Coalition

Experimentica Ltd. Presents at the ISER in Belfast, Northern Ireland - XXIII Biennial Meeting of the International Society for Eye Research September 9-13, 2018 | Belfast

The XXXIII Biennial Meeting of the International Society of Eye Research takes place this year from September 9-13th in Belfast, Northern Ireland, UK. Dr Jenni J. Hakkarainen – Acting COO of Experimentica Ltd. will present an oral presentation on a metalloporphyrin superoxide dismutase mimetic and the dry-eye disease. Dr Simon Kaja – CSO of Experimentica Ltd. will chair a session and present on cellular mechanisms of reactive astrocytosis and opportunities for glioprotection. - September 08, 2018 - Experimentica Ltd

Gensco Pharma’s Transdermal Colchicine, ColciGel®, for Treatment of Acute Gout Flares with Negligible Systemic Absorption Improving Tolerability with Less Side Effects

New transdermal therapy available for gout sufferers with negligible systemic absorption improving tolerability and minimizing side effects. ColciGel for Acute Gout Flares is now available at your participating local retail pharmacy. - June 26, 2018 - Gensco Pharma

LayerBio to Present Preclinical Results for Extended Release Glaucoma Formulation at ARVO

LayerBio will present preclinical study results at the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii on Monday, April 30. These results demonstrate the therapeutic potential of its novel extended-release travoprost formulation using LayerBio's proprietary PolyNet™ delivery technology. - April 27, 2018 - LayerBio, Inc.

Value Drug Scores Big in Pharmaceutical Returns

PharmaLink is the New Partner in Drug Returns Processing Value Drug, a top-rated wholesaler to independent pharmacies, announced another industry leading initiative with PharmaLink. Together they will now provide to all of their members a full array of services in the take back and processing of... - March 14, 2018 - PharmaLink

Experimentica Ltd. Amongst the Most Promising Finnish Young Innovative Companies

Experimentica Ltd. Amongst the Most Promising Finnish Young Innovative Companies

Experimentica Ltd. has been selected for Phase 1 of the Young Innovative Company program by Business Finland (formerly known as TEKES, The Finnish Funding Agency for Technology and Innovation). The funding awarded for the first phase is a 250,000 € grant for a period of 12... - February 21, 2018 - Experimentica Ltd

Creative BioMart to Expand Its Protein Glycosylation Labeling Service Capacity to Meet Rising Demands

Creative BioMart, a global leader in the supply of high quality protein products and efficient protein manufacturing techniques, today announced a major expansion of its Protein Glycosylation Labeling Service capacities as a response to rising customer needs and market demands for characterizing... - November 26, 2017 - Creative Biomart

Tanner Pharma Group to Attend Upcoming CPHI Worldwide Conference

Top executives from Tanner Pharma Group (“Tanner Pharma”), a Charlotte-based global pharmaceutical services company, will attend the CPhI Worldwide event on October 24 – 26 in Messe Frankfurt, Germany. Tanner Pharma leverages more than 15 years of pharma services experience to... - October 21, 2017 - Tanner Pharma Group

Drugshoppe Selected as Finalist for 2017 Innovation Conference and Showcase

Drugshoppe was selected as a finalist in the first annual pitch competition at the Houston Technology Center Innovation Conference and Showcase. Drugshoppe was picked from among many companies that applied in the fields of life sciences, aerospace, energy, IT, and transportation. Drugshoppe will... - September 14, 2017 - Drugshoppe

Pharmaceutical Company CJSC "ARAY" Announces Construction of Pharmaceutical Plant with Two Hormonal Drugs Research, Development and Production in Bishkek, Kyrgyzstan

Pharmaceutical company CJSC ARAY announced today that it is in active research and development phase of a new Hormone Replacement Therapy (HRT) drug, called SUSTADREN (TM), housed in Bishkek, Kyrgyz Republic. - August 19, 2017 - CJSC ARAY

Responsive Health Selected to Attend New Jersey Founders & Funders Event

Responsive Health Selected to Attend New Jersey Founders & Funders Event

Leader in Digital Medicine Will Attend April 27 Event. - April 25, 2017 - Rx.Health

Responsive Health Announces Strategic Expansion Into New Jersey Healthcare Market

Responsive Health Announces Strategic Expansion Into New Jersey Healthcare Market

Pioneer in Digital Medicine Expands Northeast Presence - April 19, 2017 - Rx.Health

KeyCentrix™ Announces Integration with myDataMart

FDS & myDataMart offer professional, comprehensive and affordable business solutions that immediately impact pharmacy profitability by providing tools to manage patients, third party receivables, Star Ratings, immunization opportunities, MTM cases and much, much more. By providing a deeper look into each pharmacy's data, myDataMart can help better manage pharmacy operations and increase profits. - February 23, 2017 - KeyCentrix

Experimentica Ltd. Appoints New Director of In Vivo Pharmacology

Experimentica Ltd., a global ophthalmic contract research organization (CRO) today announced the appointment of Tamuna Bolkvadze, Ph.D. to Director In Vivo Pharmacology, effective immediately. Dr. Bolkvadze joined Experimentica Ltd. earlier in 2016 as Research Scientist and has been instrumental... - October 22, 2016 - Experimentica Ltd

Tabula Rasa HealthCare to Present Medication Therapy Management Innovations at MTM Summit September 15-16, 2016

Tabula Rasa HealthCare to Present Medication Therapy Management Innovations at MTM Summit September 15-16, 2016

Tabula Rasa HealthCare's (TRHC) Medication Risk Mitigation Matrix(R) brings to Enhanced Medication Therapy Management (EMTM) the ability to identify those Medicare beneficiaries at the highest risk of an adverse drug event and mitigates that risk through personalized interventions. - September 07, 2016 - Tabula Rasa HealthCare

Press Releases 1 - 50 of 234